AQST · Aquestive Therapeutics, Inc.

The thesis

Aquestive Therapeutics' needle-free epinephrine film Anaphylm now has a fixed Food and Drug Administration (FDA) decision date of 16 March 2027, which falls outside a three-month window, so the shares are more likely to lag the S&P 500 than lead it. The company's 15 October 2026 announcement that the FDA accepted the resubmission as a Class 2 review, a six-month clock, settles the timing that the previous note left open. The third-quarter 2026 results, expected in early November, are the next test of the revenue guidance, cash and share count.

The narrative is maturing: the review class and goal date have been public since 15 October 2026, and the shares closed at $3.97 on 26 October 2026, down from $4.67 on 13 October 2026, per adjusted daily closes. That close is 43.3% below the 52-week high of $7.00. The shares are up 10.3% over three months, and the 14-day Relative Strength Index (RSI, a 0-to-100 momentum gauge where readings near 30 mark heavy selling) is 31.6.

A Class 2 designation matches what company statements reported by MarketBeat on 26 February 2026 had described, because the filing contains clinical data. Approval before 2027 would show this view is wrong. The 14 October 2026 licence of Libervant to Eton Pharmaceuticals adds cash, but it does not move the Anaphylm timeline.

Bullish and bearish views on Aquestive Therapeutics, Inc.

The bull case on Aquestive Therapeutics, Inc. (AQST), in brief: The FDA accepted the filing as complete. The bear case: The decision date is nearly five months away.

Bull case

• The FDA accepted the filing as complete. The company's 15 October 2026 release reports acceptance of the Anaphylm New Drug Application resubmission with a PDUFA (Prescription Drug User Fee Act) goal date of 16 March 2027. A finding that the filing was incomplete was the sharper regulatory risk, and it did not occur.
• The documented deficiencies were addressed directly. The FDA's 30 January 2026 Complete Response Letter cited trouble opening the pouch and placing the film correctly. The company's 17 September 2026 release reports median pouch-opening time cut to 3 seconds from 17.
• Libervant now brings in outside cash. Aquestive's 8-K of 13 October 2026 reports a $10.0 million upfront fee from Eton, up to $47.5 million in further regulatory and commercial milestones, and mid-teens royalties on net sales. Aquestive stays the exclusive manufacturer.
• An operating business sits under the catalyst. Second-quarter 2026 revenue was $13.819 million, up 38% year over year, per the 11 August 2026 earnings release. Full-year revenue guidance of $46 million to $50 million was affirmed.
• Analyst targets sit far above the price. H.C. Wainwright reiterated Buy with a $10 target on 24 August 2026, and LifeSci Capital reiterated Buy with a $10 target after the resubmission, per TipRanks. Both are well above the $3.97 close on 26 October 2026.

Bear case

• The decision date is nearly five months away. The FDA goal date of 16 March 2027 leaves no approval event inside the next three months. The shares have a review to wait on and little regulatory news to react to.
• The shares fell after the news. The close was $4.67 on 13 October 2026 and $3.97 on 26 October 2026, a window that contains both the Eton licence and the PDUFA announcement. The company's good-news items did not hold the price.
• Losses and dilution come before launch. The second-quarter net loss was $22.9 million, including an $11.7 million loss on debt extinguishment. Cash was $98.5 million at 30 June 2026 against $50.7 million of net long-term debt. Shares outstanding rose 27.37% over the year to 125.51 million (stockanalysis.com, 4 September 2026).
• Anaphylm would launch against an incumbent with payer relationships.
• Libervant does not come with a launch date. Eton's licence is subject to regulatory approvals, and the product holds tentative approval only (Aquestive and Eton 8-Ks, 13 October 2026). Full approval is tied to a competing orphan exclusivity that the previous note placed at January 2027.

Price setup

The adjusted daily close on 26 October 2026 was $3.97. That is 43.3% under the 52-week high of $7.00 and below the $4.47 200-day moving-average level reported on 4 September 2026, the level the previous note used for its invalidation. A rising gap above a moving average is not present. The 14-day RSI of 31.6 is near the zone that usually marks heavy selling.

Crowding evidence is mixed. Short interest was 20.95 million shares, 18.27% of float or 7.36 days to cover, on 4 September 2026, which amplifies moves on news in both directions. That reading is seven weeks old. An earnings report is due within about two weeks, and the company has a record of equity issuance. No insider-selling filings are in the news flow reviewed for this note.

Catalysts, next 30 days

• ~10 November 2026, est.: third-quarter 2026 results. The company reported second-quarter results on 11 August 2026, and its 2025 third-quarter report came on 5 November 2025, so the date is not yet confirmed. The report tests the $46 million to $50 million revenue guidance and shows cash and share count against $98.5 million and 125.5 million at 30 June 2026. It may also show how the $10.0 million Eton payment is recorded.
• ~31 January 2027, est.: competing orphan exclusivity expires. The previous note tied full Libervant approval to this date. It matters to Eton's milestones and to Aquestive's royalty stream.
• 16 March 2027: PDUFA goal date for Anaphylm. This is the FDA approval decision. It falls outside the next 30 days and outside a three-month window.

What would change the view

The case that the shares lag would break if the FDA acted on Anaphylm well before 16 March 2027, or if company disclosures showed the review moving forward on a faster clock. It would also weaken if third-quarter results showed revenue running above the $46 million to $50 million guidance range while the share count stayed near 125.5 million. A financing completed at a price above the current level would show buyers willing to fund the story.

On the other side, an FDA finding of deficiencies, a request for another human factors or pharmacokinetic study, or a cut to full-year revenue guidance would harden the bearish reading. A marketed equity offering before the March decision would do the same.

For price, a daily close below $3.50 would mark a break lower from the 26 October 2026 close of $3.97 and show selling continuing after the PDUFA date was set.

What it trades with

Aquestive trades on its own regulatory calendar more than on sector direction. Its Anaphylm outcome is a single-product event with a dated decision, and the shares are sensitive to small-cap biotech financing conditions because of the history of equity issuance. ARS Pharmaceuticals is the nearest read-across: neffy's coverage and sales trends bear on how Anaphylm would launch. Eton Pharmaceuticals, as licensee, has a direct stake in Libervant's regulatory path.